IRADIMED Director Converts 698 Units Into Shares

The RSUs vest in three equal annual installments beginning September 23, 2026.

Rhea-AI Filing Summary

IRADIMED CORP director Joe E. Kiani reported the conversion of 698 restricted stock units into 698 common shares on September 23, 2026. After the transaction, he directly held 1,397 restricted stock units and 698 common shares.

Insider Trade Summary

698 shares exercised/converted

Exercise 2 txns

Insider KIANI JOE E

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F1, F2	698	$0.00	$0.00
Exercise	Common Stock F1	698	--	--

Holdings After Transaction: Restricted Stock Units — 1,397 contracts (Direct); Common Stock — 698 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.
2. F2. The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on September 23, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Key Figures

Restricted stock units converted: 698 RSUs Common shares received: 698 shares Restricted stock units held after transaction: 1,397 RSUs +1 more

4 metrics

Restricted stock units converted 698 RSUs September 23, 2026

Common shares received 698 shares Upon conversion of the RSUs on September 23, 2026

Restricted stock units held after transaction 1,397 RSUs Direct holdings following the September 23, 2026 transaction

Common shares held after transaction 698 shares Direct holdings following the September 23, 2026 transaction

Key Terms

Restricted Stock Units, 2023 Equity Incentive Plan, contingent right

3 terms

Restricted Stock Units financial

"restricted stock units vest in three equal annual installments"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2023 Equity Incentive Plan financial

"under Iradimed Corporation's 2023 Equity Incentive Plan"

contingent right financial

"represents a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IRMD shares did director Joe E. Kiani receive?

On September 23, 2026, Joe E. Kiani, a director of IRADIMED CORP, had 698 restricted stock units convert into 698 common shares. Afterward, he directly held 1,397 restricted stock units and 698 common shares.

When do IRMD's restricted stock units vest?

The RSUs vest in three equal annual installments beginning September 23, 2026. Upon vesting, Kiani is to receive common shares equal to the number of RSUs that have vested.

Was Joe E. Kiani's IRMD transaction under a Rule 10b5-1 plan?

No Rule 10b5-1 plan is reported for the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 04:45 PM Accepted by SEC EDGAR 09/25/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIANI JOE E

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FLORIDA 32826

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/23/2026		M		698	A	(1)	698	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/23/2026		M			698	(2)	(2)	Common Stock	698	$0	1,397	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

2. The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on September 23, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Remarks:

	/s/ Joe E. Kiani	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)